Paul Manning
President,Chairman & Chief Executive Officer @ PBM Capital Group
Charlottesville, United States
Paul Manning is a Series A investor at PBM Capital Group in Charlottesville focused on Biotechnology and Medical. Paul B. Manning has served as the chairman of our board of directors since December 2017 and as a member of our board of directors since December 2015. Mr. Manning is the Chairman and Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies,which he founded in 2010. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of Dova Pharmaceuticals, Inc., a publicly traded pharmaceutical company, as well as various private companies. Mr. Manning was previously on the board of directors of Perrigo Corporation, Concordia Healthcare Corp. and AveXis, Inc. Mr. Manning received a B.S. in microbiology from the University of Massachusetts.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 55%
Last updated:
For AI agents: llms.txt
Industries Paul Manning invests in
Stages Paul Manning invests in
Countries Paul Manning invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (55%)
- Medical 5 (45%)
- Health Care 5 (45%)
- Therapeutics 5 (45%)
- Genetics 3 (27%)
Stage
- Series A 2 (18%)
- Series B 2 (18%)
- Post-IPO Equity 2 (18%)
- Seed 1 (9%)
- Grant 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Verrica Pharmaceuticals is a pharmaceutical company developing proprietary topical therapies for the treatment of lesional skin diseases such as Verruca vulgaris (common warts and plantar warts) and Molluscum contagiosum. Current treatment for these and similar conditions have only limited efficacy, are painful or require daily compliance for anextended treatment period to see results. | $12.5M / Post-IPO Debt / Aug 06, 2026 | ||
| Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. Wehave combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. | $150M / Post-IPO Equity / Aug 14, 2023 | ||
| The Paul and Diane Manning Institute of Biotechnology engages in the medical research that leads to new medical treatments, including cellular therapy, gene therapy, nanotechnology and drug delivery. | $300M / Grant / Jan 20, 2023 | ||
| Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases. It offers a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group.The companywas established in 2009 and is based in San Francisco, California, United States. | $30M / Series C / Aug 24, 2021 | ||
| Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $21.7M / Post-IPO Equity / Apr 13, 2021 | ||
| SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broadapplicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond. | $20M / Series A / Feb 18, 2021 | ||
| PatientsLikeMe is a personalized health network of an integrated community, health management, and real-world data platform.It helps people find new options for treatments, connect with others, and take action to improve their outcomes. The company has worked with every major pharmaceutical company and a range of government organizations to bringthe patient voice to research, development, and public policy. With more than 600,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 100 research studies.The Boston, Massachusetts-located company was founded by Ben Heywood, James Heywood, and Jeff Cole in 2004 | $26M / Venture - Series Unknown / Feb 09, 2021 | ||
| Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. Wehave combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. | $95M / Series B / Aug 05, 2020 | ||
| Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $80.5M / Series A / May 12, 2020 | ||
| Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. Wehave combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. | $30M / Seed / Apr 29, 2020 | ||
| See all 11 investments → | |||
Co-Investors
About PBM Capital Group
PBM Capital Group, LLC. is a private investment firm primarily focused on healthcare investments. Led by Paul Manning, a successful entrepreneur, it invests across all stages of corporate development– including venture capital, leveraged buyouts, growth capital, distressed/turnaround, and public equity value investing– and create value byapplying extensive industry knowledge and contacts, providing superior operational expertise and bringing an entrepreneurial spirit to attractive investment opportunities.We actively partner with our portfolio companies to drive commercial success and enhance profitability.
PBM Capital Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Benno von Buchwaldt
Director
|
|||
Jayson Rieger
SVP Business Development & Portfolio Management
|
|||
|
Paul Manning
President,Chairman & Chief Executive Officer
|
|||
Sean Stalfort
President
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Paul Manning invest in?
Paul Manning invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Paul Manning?
Public channels for Paul Manning include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Paul Manning last invest?
The most recent investment recorded for Paul Manning closed in Aug 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
